Things are looking up for the biodiesel producer, but is the stock a buy after more than doubling in the last year?
Sometimes in investing, bigger really is better. These three large-cap stocks could anchor your portfolio.
The sleepy laboratory hardware manufacturer has found itself on the radar of many investors lately.
The biopharma is wisely taking advantage of its lofty stock price to raise capital through a share offering.
The master limited partnerships of Antero Resources have merged, changed their name, switched to a new operating structure, and kept the same ticker.
The genetic testing leader announced full-year 2018 operating results, but the numbers were actually pretty poor.
The pharma company announced full-year 2018 operating results and reiterated the road map for the year ahead.
NextEra Energy Partners has a sweet relationship with the nation's largest renewable power generator -- and it pays a 4.4% dividend.
The agricultural sciences leader reported full-year 2018 operating results, then abruptly sank in early March.
The liquid biopsy pioneer has more than doubled since its IPO.
Energy storage devices of the next decade will require several times more lithium than what's on the market today.
The stock ricocheted around, but ultimately posted a monthly gain.
Investors are excited about new clinical results suggesting the small-cap biopharma is on to something big.
Quarterly earnings from around the industry suggested the epic growth opportunity isn't slowing down anytime soon.
The biopharma announced fourth-quarter 2018 operating results and reminded investors of its deep late-state pipeline.
Investors cheered the news in a fiscal first-quarter 2019 earnings report.
The stock rose in anticipation of a business update at the end of the month.
Looking for stocks you don't have to babysit? Consider these three stocks.
The company reported fourth-quarter and full-year 2018 earnings and guidance for 2019.
The pharmaceutical company may have proved Wall Street wrong, but it has a long way to go to reach its full potential -- and that's a good thing for investors.